About Lexaria

Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.

Testing conducted since 2016 has repeatedly demonstrated DehydraTECH has the ability to:

Increase bio-absorption with cannabinoids and nicotine by 5-10x—and in some instances with cannabinoids by as much as 17x—compared to standard industry formulations
Reduce time of onset from 1 – 2 hours to minutes
Mask unwanted tastes

It is also being evaluated for hypertension, oral nicotine, orally administered antiviral drugs, epilepsy, PDE5 inhibitors and more.

Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many more patents pending worldwide.

Lexaria operates five subsidiary companies to focus on its different commercial opportunities in their respective industries:

Lexaria Pharmaceutical Corp. investigates new products for hypertension, antiviral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes
Lexaria Nicotine LLC investigates oral non-combusted tobacco-derived nicotine product formats
Lexaria Hemp Corp. pursues business-to-business opportunities with cannabinoids
Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization
Lexaria Nutraceutical Corp. is focused solely on the manufacture of pharmaceutical products, or sublicensing for the manufacture of pharmaceutical products, composed of any molecule except nicotine-associated molecules

Lexaria sub-licenses the Company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.